Compare TALK & CMPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TALK | CMPX |
|---|---|---|
| Founded | 2012 | 2014 |
| Country | United States | United States |
| Employees | 521 | N/A |
| Industry | Medical/Nursing Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 788.5M | 926.7M |
| IPO Year | N/A | 2020 |
| Metric | TALK | CMPX |
|---|---|---|
| Price | $5.13 | $5.15 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 9 |
| Target Price | $6.42 | ★ $14.43 |
| AVG Volume (30 Days) | ★ 5.8M | 1.7M |
| Earning Date | 05-05-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $26.02 | N/A |
| Revenue Next Year | $21.24 | $677.91 |
| P/E Ratio | $155.55 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.22 | $1.33 |
| 52 Week High | $5.19 | $6.88 |
| Indicator | TALK | CMPX |
|---|---|---|
| Relative Strength Index (RSI) | 66.17 | 37.26 |
| Support Level | $4.59 | $4.86 |
| Resistance Level | $5.19 | $5.86 |
| Average True Range (ATR) | 0.09 | 0.29 |
| MACD | -0.02 | -0.02 |
| Stochastic Oscillator | 90.02 | 15.53 |
Talkspace Inc is a behavioral healthcare company offering access to licensed therapists, psychologists, and psychiatrists through its technology platform. It serves clients including health plans, enterprises, and individual subscribers. Therapists address various mental health conditions, while psychiatrists cater to a higher acuity demographic. Revenue stems from payor and direct-to-enterprise clients, with contracts lasting one to three years. The majority of the Company's operations and revenues are based in the United States.
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to drug the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-IO Bispecific, and CTX-8371.